KHDRBS3 and medulloblastoma: Our findings implicate hsa-miR-30b, hsa-miR-30d and KHDRBS3 as putative oncogenic target(s) of a novel recurrent medulloblastoma amplicon at 8q24.22–q24.23, which is independent of MYC amplification and unique to this disease.